Employing the synthetic chemistry methods patented by Dr. Holton and Florida State University, Taxolog, Inc., designs, synthesizes and develops novel taxane molecules intended for use in the treatment of cancer and other diseases. Taxolog's goal is to bring new drugs to patients that are more effective, safer or easier to use than the drugs that are currently available.

Taxolog synthesizes hundreds of new drugs each year in its laboratories in Fairfield, New Jersey. These drugs are evaluated in a variety of biological tests performed by our scientists in our research facility in Tallahassee, Florida, and then further screened and characterized by personnel in both locations. The ultimate goal of this undertaking is to find a drug candidate with sufficient promise to enter clinical trials. To date, three promising drugs for the treatment of cancer have emerged from our research efforts and have entered clinical trials.

SYNTHESIS AND ACTIVE PHARMACEUTICAL INGREDIENT

Taxolog's history is soundly landscaped with synthetic organic chemistry as represented by the R. Holton/FSU semi-synthesis of paclitaxel that helped establish API for the market for many years. Taxolog continues to utilize their expertise in this area and have recently demonstrated synthetic improvements for potential use with many taxanes, including a lower cost-manufacturing route for USP paclitaxel. Taxolog is pursuing the potential taxane API market with this technology.